The MARINA trial established intravitreal ranibizumab as effective for which specific subtype of choroidal neovascularisation (CNV) in AMD?
- A Minimally classic or occult (no classic) CNV ✓
- B Predominantly classic CNV
- C Purely classic CNV only
- D Polypoidal choroidal vasculopathy
Correct answer: A. Minimally classic or occult (no classic) CNV
Explanation
The MARINA trial specifically studied monthly intravitreal ranibizumab (0.3 mg and 0.5 mg) versus sham injection in patients with minimally classic or occult (no classic component) CNV in AMD. Results showed ~95% of treated patients lost fewer than 15 ETDRS letters vs 62% sham, and ~33% gained ≥15 letters. The ANCHOR trial simultaneously studied predominantly classic CNV. Together, MARINA and ANCHOR established ranibizumab across all CNV subtypes in AMD. Polypoidal choroidal vasculopathy is best treated with anti-VEGF plus photodynamic therapy.
Reference: Khurana Comprehensive Ophthalmology, 7th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.